MedTrace Logo

Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer

NCT01035437 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2012-07-02

No results posted yet for this study

Summary

This study aim is to find out what effects capecitabine, oxaliplatin and radiation therapy following photodynamic therapy have on esophageal cancer.

Conditions

  • Esophageal Neoplasm

Interventions

DRUG

HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)

HPPH in D5W, 4.0 mg/m2 infused over 1 hour

Sponsors & Collaborators

  • Roswell Park Cancer Institute

    lead OTHER

Principal Investigators

  • Nikhil Khushalani, MD · Roswell Park Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-01-31
Completion
2011-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01035437 on ClinicalTrials.gov